- In-depth discussion of case studies of products undergoing development
- Focus on commercial optimization of stem cell treatments
- Analysis in a global context and covering a diverse range of countries
List of abbreviations
About the author
Chapter 1: Introduction: stem cell science, biotechnology and the problem of commercialization
1.1 Modelling the most successful biotech business in the world
1.2 Emerging stem cell therapies and the commercialization of biotechnology
1.3 Some prospective possibilities for the stem cell industries
1.4 The limits of commercialization in the stem cell sciences
1.5 What are the most lucrative commercial models to adopt?
Chapter 2: Stem cell treatments in a global marketplace
2.1 Patients drive the market
2.2 Healthcare providers and the consumption of stem cell technologies
2.3 Stem cell tourism: is it a fraud or a worthwhile endeavour?
2.4 The lucrative potential of animal applications of stem cell products and techniques
2.5 What is the potential for market share?
Chapter 3: The role of innovation systems in the commercialization of biotechnology
3.1 The international context of stem cell science
3.2 The key components of national innovation systems
3.3 The intersection between commercialization and innovation
3.4 Globalization and innovation systems?
Chapter 4: Low-risk, low-value: adult stem cells
4.1 A brief history of adult stem cell technologies
4.2 Adult stem cell science in the twenty-first century
4.3 So where are the commercial opportunities?
Chapter 5: High-risk, high-value: embryonic stem cells
5.1 The global debate
5.2 Current clinical trials
5.3 The future of hESC research?
Chapter 6: Low-risk, low-value: iPS cells
6.1 iPSCs and the autologous solution
6.2 Imagined scenarios
6.3 The iPS cell industry?
Chapter 7: What does the future hold?